Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q3)Aug 31, 2025 | (Q2)May 31, 2025 | (Q1)Feb 28, 2025 | (FY)Nov 30, 2024 | (Q4)Nov 30, 2024 | (Q3)Aug 31, 2024 | (Q2)May 31, 2024 | (Q1)Feb 29, 2024 | (FY)Nov 30, 2023 | (Q4)Nov 30, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -343.72%-278.58K | 33.64%-481.05K | 126.61%102.37K | -785.74%-910.82K | 283.28%84.59K | 15.57%114.3K | -258.36%-724.92K | -1.88%-384.79K | 116.06%132.82K | 26.45%-46.15K |
| Net income from continuing operations | -315.12%-455.47K | -64.07%-196.4K | 36.58%-87.96K | 75.42%-582.31K | 88.92%-214.2K | -150.76%-109.72K | 32.61%-119.7K | 35.04%-138.69K | -263.45%-2.37M | -780.15%-1.93M |
| Operating gains losses | 46.43%-11.4K | 8,522.94%78.59K | -110.85%-3.62K | -123.82%-18.14K | 39.55%-29.26K | 66.57%-21.27K | -100.97%-933 | -63.76%33.32K | 109.02%76.15K | 94.25%-48.41K |
| Asset impairment expenditure | --0 | --0 | -46.41%3.1K | -93.26%105.78K | -93.63%100K | --5.78K | ---5.78K | --5.78K | 127.25%1.57M | 1,107.20%1.57M |
| Remuneration paid in stock | ---- | ---- | ---- | --0 | --0 | ---- | ---- | ---- | -33.54%161.87K | ---- |
| Other non cashItems | -7.88%-4.77K | 79.73%-3.42K | 2.89%-4.17K | -83.01%-18.35K | -83.02%7.25K | -91.50%-4.42K | -424.22%-16.89K | 90.90%-4.29K | -85.88%-10.03K | 104.60%42.67K |
| Change In working capital | -112.10%-29.51K | 38.14%-359.81K | 169.43%195.02K | -156.54%-397.79K | 36.66%220.8K | 16.94%243.93K | -207.23%-581.62K | -34.41%-280.91K | 370.25%703.59K | -84.59%161.57K |
| -Change in receivables | 423.10%180.73K | -109.06%-14.73K | -81.26%-221.42K | -57.79%189.25K | 236.01%204.78K | -1,511.99%-55.94K | -63.75%162.56K | -112.11%-122.16K | 509.10%448.35K | 114.17%60.95K |
| -Change in payables and accrued expense | -156.49%-42.33K | 30.18%-42.49K | 562.21%54.88K | -391.67%-47.17K | -116.47%-49.38K | 530.57%74.94K | 68.00%-60.86K | 88.35%-11.87K | 94.09%-9.59K | -72.93%299.9K |
| -Change in other working capital | -174.65%-167.91K | 55.72%-302.59K | 346.17%361.56K | -303.85%-539.87K | 132.82%65.4K | -1.98%224.93K | -340.50%-683.32K | -196.81%-146.87K | 2,210.37%264.84K | -153.80%-199.27K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -343.72%-278.58K | 33.64%-481.05K | 126.61%102.37K | -785.74%-910.82K | 283.28%84.59K | 15.57%114.3K | -258.36%-724.92K | -1.88%-384.79K | 116.06%132.82K | 26.45%-46.15K |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 61,090.86%120.15K | 661.82%154.03K | 126.67%2.18K | -82.33%25.31K | 108.25%4.33K | -100.67%-197 | -83.53%20.22K | -97.80%960 | 320.95%143.2K | -133.14%-52.45K |
| Capital expenditure reported | ---- | -67.43%1.09K | 40.19%-1.99K | ---- | ---- | ---4.62K | --3.33K | 21.83%-3.33K | ---- | ---- |
| Net PPE purchase and sale | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | 472.53%88.35K | ---53.93K |
| Net business purchase and sale | --0 | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
| Interest received (cash flow from investment activities) | 7.88%4.77K | -48.91%3.42K | -2.89%4.17K | 71.45%18.35K | 98.51%2.94K | 91.50%4.42K | 108.01%6.7K | 16.21%4.29K | 6.31%10.7K | -67.18%1.48K |
| Net other investing changes | ---- | ---- | ---- | -84.24%6.96K | 138,500.00%1.39K | -461,400.00%-4.62K | ---- | ---- | --44.15K | --1 |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 61,090.86%120.15K | 661.82%154.03K | 126.67%2.18K | -82.33%25.31K | 108.25%4.33K | -100.67%-197 | -83.53%20.22K | -97.80%960 | 320.95%143.2K | -133.14%-52.44K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 0 | 0 | 0 | 895.56K | 442.74K | 0 | 0 | 452.82K | 0 | 0 |
| Net issuance payments of debt | --0 | --0 | --0 | ---40K | --0 | --0 | --0 | ---40K | --0 | --0 |
| Net common stock issuance | --0 | --0 | --0 | --935.56K | --442.74K | --0 | --0 | --492.82K | --0 | --0 |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | --0 | --0 | --0 | --895.56K | --442.74K | --0 | --0 | --452.82K | --0 | --0 |
| Net cash flow | ||||||||||
| Beginning cash position | 78.85%1.03M | 7.30%1.36M | 1.35%1.25M | 19.29%1.24M | -47.11%705.61K | -50.11%573.98K | 95.41%1.27M | 19.29%1.24M | -10.93%1.04M | 45.97%1.33M |
| Current changes in cash | -238.84%-158.42K | 53.59%-327.02K | 51.55%104.55K | -96.36%10.05K | 639.24%531.65K | -11.02%114.11K | -221.39%-704.7K | 120.65%68.99K | 277.65%276.03K | -203.24%-98.59K |
| Effect of exchange rate changes | -28.57%12.52K | -199.60%-8.85K | 115.98%5.58K | 108.63%6.58K | 5,563.53%15.07K | -68.37%17.52K | 111.13%8.89K | 32.82%-34.9K | -370.11%-76.19K | -98.99%266 |
| End cash Position | 24.81%880.68K | 78.85%1.03M | 7.30%1.36M | 1.35%1.25M | 1.35%1.25M | -47.11%705.61K | -50.11%573.98K | 95.41%1.27M | 19.29%1.24M | 19.29%1.24M |
| Free cash from | -342.92%-277.67K | 33.48%-479.96K | 125.86%100.38K | -785.74%-910.82K | 283.28%84.59K | 15.57%114.3K | -256.18%-721.58K | -1.61%-388.12K | 110.60%132.82K | 82.22%-46.15K |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.